Clinical Trial Update: Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for furmonertinib in patients with leptomeningeal metastases associated with EGFR-mutated non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN